Cartherics – CAR-NK Manufacturing Expansion

Summary Cartherics and Catalent have expanded their manufacturing partnership to support development and commercialization of iPSC-derived CAR-NK cell therapies. The agreement strengthens access to Catalent’s cGMP-compliant iPSC platform, supporting multiple programs including lead candidate CTH-401. What Happened Cartherics entered an expanded commercial license agreement with…